What are the potential consequences and health outcomes of untreated chronic

Guideline-aligned answer with reasoning, red flags and references. Clinically reviewed by Dr Kola Tytler MBBS CertHE MBA MSt MRCGP.

Posted: 6 August 2026Updated: 6 August 2026 Guideline-Aligned (High Confidence) Clinically Reviewed

Untreated CIDP can cause progressive and potentially irreversible peripheral nerve disability. The available evidence specifically supports ongoing clinical deterioration in disability, strength, hand function and daily activities when effective immune treatment is withdrawn or absent in people with active CIDP, although the exact untreated long-term trajectory varies substantially between individuals.

  • Progressive motor disability: CIDP is suggested by subacute progression of proximal and distal motor and sensory symptoms over 8 weeks, and untreated active disease may therefore continue to impair walking, transfers, stair climbing, hand function and other activities of daily living.
  • Loss of strength and dexterity: During IVIg withdrawal, trial participants with CIDP developed clinically evident deterioration; re-treatment improved disability, grip strength and MRC strength measures in most participants, supporting that untreated active disease is associated with worsening motor function.
  • Reduced mobility and falls risk: Sensory loss, imbalance, gait incoordination and weakness can lead to gait instability and falls, with consequent need for falls prevention, physical therapy and potentially increasing care support.
  • Sensory symptoms and neuropathic pain: Ongoing nerve dysfunction may cause numbness, tingling, burning, electric-shock sensations, altered temperature perception, hyperalgesia or allodynia, with effects on sleep and mood.
  • Functional and participation restrictions: Persistent weakness, sensory impairment and impaired balance can restrict independence, employment, driving, domestic activities and social participation; in a CIDP outcome study, clinically relevant improvements in disability, grip strength or muscle strength were seen after treatment in patients who had deteriorated off treatment, indicating these domains are vulnerable during untreated disease activity.
  • Potential accumulation of fixed impairment: Recurrent or sustained inflammatory demyelinating activity can leave residual deficits even when subsequent treatment improves symptoms, so delaying recognition of clinically meaningful deterioration may reduce the opportunity to preserve function; however, the supplied sources do not quantify the long-term risk of irreversible disability specifically in never-treated CIDP.
  • Heterogeneous course rather than a uniform prognosis: Not every person with CIDP will deteriorate at the same rate, and some may have periods of stability, but randomized withdrawal data show that placebo-treated participants relapsed more often than those receiving efgartigimod, with clinical deterioration defined by worsening on the adjusted INCAT disability scale.

Magnitude of untreated deterioration in trial populations: In the ADHERE randomized-withdrawal study, 53.6% of placebo-treated participants with treatment-responsive CIDP relapsed, compared with 27.9% receiving efgartigimod; placebo participants had a median time to confirmed clinical deterioration of 140 days.

In the PATH study run-in phase, all participants had IVIg dependence confirmed by clinically evident deterioration during IVIg withdrawal of up to 12 weeks, and 91% subsequently improved in at least one measure of disability, grip strength or muscle strength after IVIg treatment.

Primary-care implications: A patient with new or worsening symmetrical proximal and distal weakness, sensory loss, gait decline, falls, or loss of hand function requires urgent neurological reassessment rather than attribution of decline solely to chronic symptoms, because CIDP is a subacute motor and sensory neuropathy requiring secondary-care management.

Monitor and document functional change longitudinally, including walking, stairs, rising from a chair, hand function, falls, pain, sleep, mood and ability to perform daily activities; address foot care and ulcer prevention where sensory loss is present, and involve falls services or physiotherapy where appropriate.

Related Knowledge Topics

Educational content only. Always verify information and use clinical judgement.